Scholarlink

Background <p>Preeclampsia is a rapidly progressing pregnancy-specific multi-systemic syndrome that is the leading cause of maternal and neonatal morbidity and mortality. Lactate dehydrogenase (LDH) is a valuable and potential biomarker for predicting the severity of Preeclampsia.</p> Objectives <p>To assess the level of LDH in women with preeclampsia and to correlate its level with the severity of the disease and maternal/perinatal outcomes.</p> Patients and methods <p>This prospective case-control study was conducted at Sulaimani Maternity Teaching Hospital, Sulaimaniyah, Iraq, from March 1st, 2021, to June 30th, 2022, on 150 pregnant women in 3rd trimester of their pregnancy. Patients (<i>n</i> = 100) were diagnosed with mild and severe Preeclampsia. Serum LDH level was measured and correlated with the severity of the disease and maternal/perinatal outcomes.</p> Results <p>LDH was significantly (<i>p</i> = 0.001) elevated in preeclampsia groups compared to the control group. The mild preeclampsia group had a mean LDH level of 302.9 ± 138.5 IU/L, while the severe preeclampsia group had a mean level of 488.6 ± 223.4 IU/L. Also, maternal complications, stillbirth rate, and neonatal intensive Care Unit (NICU) admission were higher in women with high LDH levels.</p> Conclusions <p>The serum LDH level is high in women with preeclampsia and correlated with the disease severity as well as maternal and perinatal outcomes. So, serum LDH may be a valuable biomarker for predicting the severity of preeclampsia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum lactate dehydrogenase level in preeclampsia and its correlation with disease severity, maternal and perinatal outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月10日

查看全文
  • Sallama Kamel Nasir,
  • Rozhan Yassin Khalil,
  • Maryam Bakir Mahmood,
  • Aveen Saadi Dawd

摘要

Background

Preeclampsia is a rapidly progressing pregnancy-specific multi-systemic syndrome that is the leading cause of maternal and neonatal morbidity and mortality. Lactate dehydrogenase (LDH) is a valuable and potential biomarker for predicting the severity of Preeclampsia.

Objectives

To assess the level of LDH in women with preeclampsia and to correlate its level with the severity of the disease and maternal/perinatal outcomes.

Patients and methods

This prospective case-control study was conducted at Sulaimani Maternity Teaching Hospital, Sulaimaniyah, Iraq, from March 1st, 2021, to June 30th, 2022, on 150 pregnant women in 3rd trimester of their pregnancy. Patients (n = 100) were diagnosed with mild and severe Preeclampsia. Serum LDH level was measured and correlated with the severity of the disease and maternal/perinatal outcomes.

Results

LDH was significantly (p = 0.001) elevated in preeclampsia groups compared to the control group. The mild preeclampsia group had a mean LDH level of 302.9 ± 138.5 IU/L, while the severe preeclampsia group had a mean level of 488.6 ± 223.4 IU/L. Also, maternal complications, stillbirth rate, and neonatal intensive Care Unit (NICU) admission were higher in women with high LDH levels.

Conclusions

The serum LDH level is high in women with preeclampsia and correlated with the disease severity as well as maternal and perinatal outcomes. So, serum LDH may be a valuable biomarker for predicting the severity of preeclampsia.